Literature DB >> 32435394

Synthesis and Antiproliferative Activity of Nitric Oxide-Donor Largazole Prodrugs.

Matteo Borgini1, Claudio Zamperini1,2, Federica Poggialini1, Luca Ferrante3, Vincenzo Summa4, Maurizio Botta1,2,5, Romano Di Fabio3,4.   

Abstract

The marine natural product Largazole is the most potent Class I HDAC inhibitor identified to date. Since its discovery, many research groups have been attracted by the structural complexity and the peculiar anticancer activity, due to its capability to discriminate between tumor cells and normal cells. Herein, we discuss the synthesis and the in vitro biological profile of hybrid analogues of Largazole, as dual HDAC inhibitor and nitric oxide (NO) donors, potentially useful as anticancer agents. In particular, the metabolic stability of the modified thioester moiety of Largazole, bearing the NO-donor function/s, the in vitro release of NO, and the antiproliferative activity in tumor cell lines are presented.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32435394      PMCID: PMC7236235          DOI: 10.1021/acsmedchemlett.9b00643

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  35 in total

1.  Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation.

Authors:  Pravin Bhansali; Christin L Hanigan; Robert A Casero; L M Viranga Tillekeratne
Journal:  J Med Chem       Date:  2011-10-10       Impact factor: 7.446

Review 2.  Nitric oxide physiology and pathology.

Authors:  David G Hirst; Tracy Robson
Journal:  Methods Mol Biol       Date:  2011

3.  A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling.

Authors:  Yuqing Liu; Zhuo Wang; Jianing Wang; Wingchi Lam; Shuqin Kwong; Furong Li; Scott L Friedman; Shuyan Zhou; Qi Ren; Zhengshuang Xu; Xingen Wang; Ling Ji; Shoubin Tang; Hui Zhang; Eric L Lui; Tao Ye
Journal:  Liver Int       Date:  2012-12-26       Impact factor: 5.828

4.  Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.

Authors:  Yanxia Liu; Lilibeth A Salvador; Seongrim Byeon; Yongcheng Ying; Jason C Kwan; Brian K Law; Jiyong Hong; Hendrik Luesch
Journal:  J Pharmacol Exp Ther       Date:  2010-08-25       Impact factor: 4.030

5.  Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity.

Authors:  Konstantin Chegaev; Chiara Riganti; Loretta Lazzarato; Barbara Rolando; Stefano Guglielmo; Ivana Campia; Roberta Fruttero; Amalia Bosia; Alberto Gasco
Journal:  ACS Med Chem Lett       Date:  2011-04-04       Impact factor: 4.345

6.  Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold.

Authors:  Albert A Bowers; Nathan West; Tenaya L Newkirk; Annie E Troutman-Youngman; Stuart L Schreiber; Olaf Wiest; James E Bradner; Robert M Williams
Journal:  Org Lett       Date:  2009-03-19       Impact factor: 6.005

Review 7.  Nitric oxide and cancer: a review.

Authors:  Sheetal Korde Choudhari; Minal Chaudhary; Sachin Bagde; Amol R Gadbail; Vaishali Joshi
Journal:  World J Surg Oncol       Date:  2013-05-30       Impact factor: 2.754

8.  FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

Authors:  H Nakajima; Y B Kim; H Terano; M Yoshida; S Horinouchi
Journal:  Exp Cell Res       Date:  1998-05-25       Impact factor: 3.905

9.  S-Nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons.

Authors:  Alexi Nott; P Marc Watson; James D Robinson; Luca Crepaldi; Antonella Riccio
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

Review 10.  Role of Gasotransmitters in Oxidative Stresses, Neuroinflammation, and Neuronal Repair.

Authors:  Ulfuara Shefa; Seung Geun Yeo; Min-Sik Kim; In Ok Song; Junyang Jung; Na Young Jeong; Youngbuhm Huh
Journal:  Biomed Res Int       Date:  2017-03-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.